• 1
    Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P & Zeillinger R (1997) EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17, 613619.
  • 2
    Nonomura A, Ohta G, Nakanuma Y, Izumi R, Mizukami Y, Matsubara F, Hayashi M, Watanabe K & Takayanagi N (1988) Simultaneous detection of epidermal growth factor receptor (EGF–R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8, 157166.
  • 3
    Salomon DS, Brandt R, Ciardiello F & Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183232.
  • 4
    Hur BU, Yoon JB, Liu LK & Cha SH (2010) Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG–19–11, with subnanomolar affinity from naive immunoglobulin repertoires using a hierarchical antibody library system. Immunol Lett 134, 5561.
  • 5
    Zhou XK, Qiu J, Wang Z, Huang NY, Li XL, Li Q, Zhang YB, Zhao CJ, Luo C, Zhang NN et al. (2012) In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol 138, 10811090.
  • 6
    Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6, 343357.
  • 7
    Pei XY, Holliger P, Murzin AG & Williams RL (1997) The 2.0–Å resolution crystal structure of a trimeric antibody fragment with noncognate VH–VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 94, 96379642.
  • 8
    Dolezal O, Pearce LA, Lawrence LJ, McCoy AJ, Hudson PJ & Kortt AA (2000) ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng 13, 565574.
  • 9
    Power BE, Doughty L, Shapira DR, Burns JE, Bayly AM, Caine JM, Liu Z, Scott AM, Hudson PJ & Kortt AA (2003) Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci 12, 734747.
  • 10
    Le Gall F, Reusch U, Moldenhauer G, Little M & Kipriyanov SM (2004) Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods 285, 111127.
  • 11
    Hudson PJ & Kortt AA (1999) High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231, 177189.
  • 12
    Holliger P & Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23, 11261136.
  • 13
    Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor × CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 40364042.
  • 14
    Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, Sone Y, Asano R & Kumagai I (2008) Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283, 11561166.
  • 15
    Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M & Kumagai I (2011) Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv) the case of the hEx3 diabody. J Biol Chem 286, 18121818.
  • 16
    Asano R, Nakayama M, Kawaguchi H, Kubota T, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T et al. (2012) Construction and humanization of a functional bispecific EGFR CD16 diabody using a refolding system. FEBS J 279, 223233.
  • 17
    Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Pluckthun A & Pack P (1996) Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol 157, 29892997.
  • 18
    Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U & Pluckthun A (2001) Tumor targeting of mono-, di-, and tetravalent anti-p185(HER–2) miniantibodies multimerized by self-associating peptides. J Biol Chem 276, 1438514392.
  • 19
    Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y et al. (2011) In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep 26, 949955.
  • 20
    Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T et al. (2007) Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 282, 2765927665.
  • 21
    Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M et al. (2010) Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 285, 2084420849.
  • 22
    Nagorsen D & Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317, 12551260.
  • 23
    Keating GM (2010) Panitumumab. A review of its use in metastatic colorectal cancer. Drugs 70, 10591078.
  • 24
    Orita T, Tsunoda H, Yabuta N, Nakano K, Yoshino T, Hirata Y, Ohtomo T, Nezu J, Sakumoto H, Ono K et al. (2005) A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 105, 562566.
  • 25
    Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S, Wakahara Y, Tsuchiya M, Yamada-Okabe H & Fukushima N (2005) Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 29, 445450.
  • 26
    Kortt AA, Dolezal O, Power BE & Hudson PJ (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 18, 95108.
  • 27
    Asano R, Kumagai T, Nagai K, Taki S, Shimomura I, Arai K, Ogata H, Okada M, Hayasaka F, Sanada H et al. (2013) Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel 26, 359367.
  • 28
    Le Gall F, Kipriyanov SM, Moldenhauer G & Little M (1999) Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 453, 164168.
  • 29
    Kelly MP, Lee FT, Tahtis K, Power BE, Smyth FE, Brechbiel MW, Hudson PJ & Scott AM (2008) Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm 23, 411423.
  • 30
    Asano R, Sone Y, Ikoma K, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Eng Des Sel 21, 597603.
  • 31
    Boersma YL & Pluckthun A (2011) DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 22, 849857.
  • 32
    Lofblom J, Frejd FY & Stahl S (2011) Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 22, 843848.
  • 33
    Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grutter MG & Pluckthun A (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22, 575582.
  • 34
    Boersma YL, Chao G, Steiner D, Wittrup KD & Pluckthun A (2011) Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 286, 4127341285.
  • 35
    Bayly AM, Kortt AA, Hudson PJ & Power BE (2002) Large-scale bacterial fermentation and isolation of scFv multimers using a heat-inducible bacterial expression vector. J Immunol Methods 262, 217227.
  • 36
    Takemura S, Asano R, Tsumoto K, Arai T, Sakurai N, Kodama H, Yoshida H, Katayose Y, Suzuki M, Matsuno S et al. (2000) Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells. FEBS Lett 476, 266271.
  • 37
    Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T & Matsuno S (1995) Establishment of a new extrahepatic bile duct carcinoma cell line, TFK–1. Tohoku J Exp Med 177, 6171.
  • 38
    Fan Z, Lu Y, Wu X & Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269, 2759527602.
  • 39
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG & Jakobovits A (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59, 12361243.